Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials

Evaluation of the Change of Outcomes over a Ten-Year Period in Patients with Stage III Colon Cancer: Pooled Analysis of 6501 Patients Treated with Fluorouracil, Leucovorin, and Oxaliplatin in the ACCENT Database

(2020) M.E. Salem et al.   ANNALS OF ONCOLOGY

Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group

(2020) T. André et al.   ANNALS OF ONCOLOGY

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study

(2020) F. Pagès et al.   ANNALS OF ONCOLOGY

Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project

(2019) J Souglakos et al.   ANNALS OF ONCOLOGY

New Guidelines for Statistical Reporting in the Journal

(2019) David Harrington et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer

(2019) Takayuki Yoshino et al.   JAMA Oncology

LBA30_PRAnalysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration

(2019) J Taieb et al.   ANNALS OF ONCOLOGY

The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?

(2018) A Sobrero et al.   ANNALS OF ONCOLOGY

FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial

(2018) Alberto Sobrero et al.   JOURNAL OF CLINICAL ONCOLOGY

Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial

(2018) Thierry André et al.   JOURNAL OF CLINICAL ONCOLOGY

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial

(2018) Timothy J Iveson et al.   LANCET ONCOLOGY

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

(2018) Axel Grothey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer

(2016) Alexandra Lapeyre-Prost et al.   Clinical Colorectal Cancer

Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes

(2015) James Fleshman et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According toBRAFMutation and Mismatch Repair Status of the MOSAIC Study

(2015) Thierry André et al.   JOURNAL OF CLINICAL ONCOLOGY

A Randomized Trial of Laparoscopic versus Open Surgery for Rectal Cancer

(2015) H. Jaap Bonjer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer

(2011) Daniel G. Haller et al.   JOURNAL OF CLINICAL ONCOLOGY